<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NILUTAMIDE</span><br/>(ni-lu'ta-mide)<br/><span class="topboxtradename">Nilandron<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">antiandrogen</span><br/><b>Prototype: </b>Flutamide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonsteroidal with antiandrogen activity.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks the effects of testosterone at the androgen receptor sites, thus preventing the normal androgenic response.</p>
<h1><a name="uses">Uses</a></h1>
<p>Use with surgical castration for metastatic prostate cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe hepatic impairment; severe respiratory insufficiency; hypersensitivity to nilutamide.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C) and Asian patients relative to interstitial pneumonitis. Safety and effectiveness in children are not
         established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q.d. <small>x</small> 30 d, then reduce to 150 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give first dose on the day of or day after surgical castration.</li>
<li>Store below 15°30° C (59°86° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Hot flushes, impotence, decreased libido, malaise,</span> edema, weight loss, arthritis. <span class="typehead">CNS:</span> Nervousness, paresthesias. <span class="typehead">CV:</span> Angina, heart failure, syncope. <span class="typehead">GI:</span> Diarrhea, GI hemorrhage, melena, dry mouth. <span class="typehead">Respiratory:</span> Cough, interstitial lung disease, rhinitis. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Other:</span> Alcohol intolerance. <span class="typehead">Special Senses:</span> Cataracts, photophobia. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in the liver. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 3850 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain baseline chest x-ray before treatment and periodically thereafter.</li>
<li>Closely monitor for S&amp;S of pneumonitis; at the first sign of adverse pulmonary effects, withhold drug and notify physician.
            Abnormal ABGs may indicate need to discontinue drug.
         </li>
<li>Lab tests: Monitor liver function before beginning treatment and at 3-mo intervals; if serum transaminases increase &gt;23
            times upper limit of normal, discontinue treatment.
         </li>
<li>Monitor patients taking phenytoin, theophylline, or warfarin closely for toxic levels of these drugs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report following S&amp;S of adverse effects on lungs to physician immediately: Development of chest pain, dyspnea, and cough with
            fever.
         </li>
<li>Report S&amp;S of liver injury to physician: Jaundice, dark urine, fatigue, or signs of GI distress including nausea, vomiting,
            abdominal pain.
         </li>
<li>Use caution when moving from lighted to dark areas because the drug may slow visual adaptation to darkness. Tinted glasses
            may partially alleviate the problem.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>